The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...

As demand for GLP-1 medications surges, Hydreight’s inclusion of Liraglutide introduces a stable, patent-free, and clinically proven option—ideal for patients and providers seeking consistent ...

The latest attempt focuses on liraglutide, an older, once-daily injectable product in Novo Nordisk's GLP-1 agonist franchise sold as Victoza and Xultophy for diabetes and Saxenda for obesity.

is pleased to announce the expansion of its VSDHOne platform with the launch of Liraglutide. This addition marks a strategic expansion of Hydreight’s growing GLP-1 weight management and wellness ...